CTRI/2022/12/048219
Completed
Phase 4
â??Dermatological safety evaluation of test products by Primary Irritation Patch Test within 24 hours of application on healthy human all skin typesâ?¿.
Vasu Health Care0 sites24 target enrollmentTBD
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Vasu Health Care
- Enrollment
- 24
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Subjects who are willing to participate in the study and sign the informed consent document and comply with the trial procedure.
- •2\.Healthy Men \& women volunteers are chosen in ratio of 1:1 aged \> 35 and \< 60 years.
- •3\.Having healthy skin on test area as assessed by dermatological examination and donâ??t have history of allergy.
Exclusion Criteria
- •1\.Pregnant/nursing mothers.
- •2\.Scars, excessive terminal hair, or tattoos on the studied area.
- •3\.Dermatological infection/pathology on level of studied area.
- •4\.Hypersensitivity, allergy antecedent (to any cosmetic product, raw material)
- •5\.Chronic illness which may influence the outcome of the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 4
Safety evaluation of test products on healthy skin typeCTRI/2023/03/050796Dabur India Limited24
Completed
Not Applicable
Safety testing of cosmetic products by patch testCTRI/2021/12/038826Arbro pharmaceutical Pvt Ltd24
Completed
Not Applicable
Safety evaluation of cosmetic products by patch testCTRI/2022/02/040338Arbro pharmaceutical Pvt Ltd24
Completed
Not Applicable
Safety testing of cosmetic products by PIPT(Primary Irritation Patch Test)CTRI/2022/02/039947Arbro pharmaceutical Pvt Ltd24
Not yet recruiting
Not Applicable
To check dermatological safety of test products by 24 hours patch test on adult healthy human subjectsCTRI/2024/06/069652Kayura Effect LLP